Bora CDMO Bora CDMO

X
[{"orgOrder":0,"company":"AiPing Pharmaceutical Inc","sponsor":"ECI Pharmaceuticals LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ECI Pharmaceuticals LLC Enters into Exclusive U.S. Distribution Agreement for Ibuprofen","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by AiPing Pharmaceutical Inc

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            According to IQVIA data for the 12 months ended December 2020, total U.S. generic sales of Ibuprofen tablets 400 mg, 600 mg, 800 mg was approximately $110 million. Generic Folic Acid tablets 1 mg were approximately $20 million for the same period.

            Lead Product(s): Ibuprofen

            Therapeutic Area: Neurology Product Name: Ibuprofen-Generic

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: ECI Pharmaceuticals LLC

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement April 23, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY